Live
FierceBiotechIcon, Advarra partnership aims to optimize trials, expand accessLonza NewsLonza Group AG stock faces pressure amid board changes ahead of 2026 annual meeting - AD HOC NEWS10x Genomics BlogVanguard amends 13G for 10X Genomics (NASDAQ: TXG) reporting 0 shares - Stock TitanCellPan-neurodegeneration proteomics reveals disease subtypes and molecular signaturesFierceBiotechMedtronic, Biotronik heart hardware make strides in conduction system pacingFierceBiotechGE HealthCare claims photon-counting CT clearance from FDACytiva (Google News)Cytiva-SR-TIGET Joint Venture Addresses Gene Therapy Bottlenecks - Inside Precision MedicineBioPharma DiveRA Capital targets China with latest SPAC dealIlluminaIllumina Inc. stock faces headwinds amid Grail divestiture scrutiny and biotech sector slowdown - AD HOC NEWSWatersWaters Corporation stock refinances $3.5 billion debt with senior notes offering amid stable analyst - AD HOC NEWSCytiva (Google News)Cytiva and Yoshindo advance domestic biosimilar manufacturing in Japan - BioSpectrum AsiaFierceBiotechShionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream
Endpoints News Jan 8, 2026

Former Genentech leaders’ protein degrader startup EpiBiologics nets $107M

Former Genentech leaders’ protein degrader startup EpiBiologics nets $107M

Original
Body unavailable. Use the original source.

Directory

59 All